425: ReShape Lifesciences Urges Shareholder Approval for Vyome Merger and Asset Sale

ReShape Lifesciences Inc. is urging stockholders to vote in favor of proposals to merge with Vyome Therapeutics, Inc. and sell substantially all assets to Biorad, aiming to transform the company and focus on immune-inflammatory assets.

Summary

• ReShape Lifesciences Inc. is seeking stockholder approval for a transformative transaction involving a merger with Vyome Therapeutics, Inc., a private clinical-stage company focused on immuno-inflammatory and rare diseases.
• Concurrently, ReShape plans to sell substantially all of its assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd. (collectively, Biorad).
• Stockholders are asked to vote FOR three key proposals at the Special Meeting on July 24, 2025: (1) issuance of common stock for the transaction, (2) approval of the asset sale to Biorad, and (3) amendments to the certificate of incorporation for post-closing Board composition.
• The ReShape Board of Directors unanimously recommended these proposals, deeming them advisable and in the best interests of the company and its stockholders.
• Independent proxy advisory firms ISS and Glass Lewis have also recommended in favor of Proposals 1, 2, and 3.

Sentiment

Score: 8

Explanation: The document presents a highly positive and urgent tone, strongly advocating for the proposed merger and asset sale, emphasizing unanimous board support, independent advisory firm recommendations, and perceived benefits for common shareholders and the company's future strategic direction.

Positives

• The transaction is unanimously recommended by the ReShape Board of Directors as being in the best interests of ReShape and its stockholders.
• Independent proxy advisory firms ISS and Glass Lewis have both recommended in favor of the proposals.
• ReShape's current Series C Preferred Stock holders have agreed to reduce their liquidation preference, providing additional opportunity for common shareholders to gain value.
• The transaction will allow ReShape to evolve by focusing on advancing the development of the combined company's immune-inflammatory assets.
• It aims to identify additional opportunities between the world-class Indian innovation corridor and the U.S. Market.

Future Outlook

The combined company will focus on advancing the development of immune-inflammatory assets and identifying additional opportunities between the Indian innovation corridor and the U.S. Market, marking a significant evolution for ReShape.

Management Comments

• "We are asking that you vote FOR each of the proposals on the agenda, including Proposals 1, 2, and 3 related to (1) the issuance of shares of our common stock, (2) the approval of the sale of substantially all of ReShapes assets, and (3) amending our certificate of incorporation to implement the post-closing composition of our Board of Directors, each in connection with our transaction with Vyome Therapeutics, Inc."
• "Each of the proposals presented in the proxy statement has been unanimously recommended by the ReShape Board of Directors."
• "These proposals will allow ReShape to take the next step in its evolution by focusing on advancing the development of the combined companys immune-inflammatory assets and identifying additional opportunities between the world-class Indian innovation corridor and the U.S. Market."
• "After a thorough strategic review, the ReShape Board of Directors unanimously determined that a merger with Vyome, a private clinical-stage company targeting immuno-inflammatory and rare diseases, and a simultaneous sale of ReShapes assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd. (together, Biorad), are advisable and in the best interests of ReShape and its stockholders."
• "To successfully execute ReShapes transformation, it is imperative that stockholders vote in favor of each proxy proposal on the agenda."

Industry Context

This transaction reflects a trend in the biotech and healthcare sectors where companies seek strategic mergers and asset divestitures to streamline operations, focus on core therapeutic areas (like immuno-inflammatory diseases), and leverage international partnerships (e.g., India-U.S. corridor) for innovation and market access. It also highlights the role of private clinical-stage companies in M&A activities.

Management Changes

Corporate Governance

Related Party Transactions

• The sale of substantially all of ReShape's assets is to Ninjour Health International Limited, which is described as an "affiliate of Biorad Medisys, Pvt. Ltd.", indicating a related party transaction.

Stakeholder Impact

• Shareholders: Potential for increased value through the reduction of Series C Preferred Stock liquidation preference and focus on new immune-inflammatory assets. Required to vote on the transaction.
• Employees: Implied shift in focus to immune-inflammatory assets, potentially impacting existing roles or creating new ones within the combined entity.
• Customers: Current customers of ReShape's divested assets will transition to Biorad. Future customers will be related to the combined company's immune-inflammatory focus.

Next Steps

• Stockholders to vote on Proposals 1, 2, and 3 at the Special Meeting on July 24, 2025.
• If approved, ReShape will proceed with the merger with Vyome and the asset sale to Biorad.
• The combined company will focus on advancing immune-inflammatory assets and identifying new opportunities.

Key Dates

Recommendation

Keywords

ReShape Lifesciences, Vyome Therapeutics, Biorad Medisys, Ninjour Health International, Merger, Asset Sale, SEC Filing, Proxy Solicitation, Stockholder Vote, Immuno-inflammatory Diseases, Rare Diseases, Corporate Transformation, Biotech M&A, Corporate Governance